# Efficacy and Safety of Iguratimod in Patients With Hand Osteoarthritis (ESIGO)

> **NCT05216757** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Peking University People's Hospital** · enrollment: 150 (estimated)

## Conditions studied

- Hand Osteoarthritis
- Inflammatory Arthritis

## Interventions

- **DRUG:** Iguratimod
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT05216757
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2022-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05216757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05216757, "Efficacy and Safety of Iguratimod in Patients With Hand Osteoarthritis (ESIGO)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05216757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*